I-Mab(IMAB) - 2024 Q4 - Annual Report

Exhibit 99.1 I-Mab Reports Full Year 2024 Financial Results and Provides Business Update ROCKVILLE, MD, April 3, 2025 – I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced financial results for the full year ended December 31, 2024, and highlighted recent pipeline progress and business updates. Givastomig is being jointly developed through a global partnership with ABL Bio, in ...